REGENXBIO Presents Positive One Year Data from Phase II ALTI

ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2...

Related Keywords

Arizona , United States , Rockville , California , San Francisco , American , Steve Pakola , Peter Kaiser , Chris Brinzey , Dana Cormack , Mark Barakat , American Academy Of Ophthalmology , Technology Platform , Exchange Commission , Cole Eye Institute , Corporate Communications , Technology Platform Licensees , Clearside Biomedical Inc , Ophthalmology Research , Securities Exchange , Cleveland Clinic Lerner College Of Medicine , Nasdaq , Diabetic Retinopathy Severity Scale , American Academy , Retinal Consultants , Chief Medical Officer , Safety Summary , Corrected Visual Acuity , Chaney Family Endowed Chair , Cleveland Clinic Lerner College , Clearside Biomedical , Platform Licensees , Securities Act , Securities Exchange Act , Financial Condition , Regenxbio Inc , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,